Journalist. Lots of thoughts about health care, higher education, politics and sports. Back in the U.S.

China Banning U.S. Professors Elicits Silence From Colleges

bloomberg.com — They call themselves the "Xinjiang 13." They have been denied permission to enter China, prohibited from flying on a Chinese airline and pressured to adopt China-friendly views. To return to China, two wrote statements disavowing support for the independence movement in Xinjiang province. They aren't exiled Chinese dissidents.

China Halts U.S. Academic Freedom at Classroom Door for Colleges

bloomberg.com — In the 25 years Johns Hopkins University and Nanjing University have run a joint campus in China, it's never published an academic journal. When American student Brendon Stewart tried last year, he found out why.

How the NHS Is Locking Out Britain's Digital-Health Startups

bloomberg.com — Peter Hames was born in the northern English city of Leeds, educated at Oxford, and founded a digital health startup in London in 2010. Six months ago, he and his company moved to San Francisco. Hames had the backing of doctors, patients and venture capitalists for Sleepio, an online insomnia treatment.
Aug 14, 2015

Britain's NHS is great -- unless you're an entrepreneur trying to build an e-health startup bloom.bg/1J3AOvq via @business

Aug 14, 2015

RT @rocks_david: Britain's NHS is great -- unless you're an entrepreneur trying to build an e-health startup bloom.bg/1J3AOvq via @business

Aug 14, 2015

The #UK could be a global hub for health startups, but the NHS is locking them out, @Ostaley writes: bloom.bg/1J3AOvq

Aug 14, 2015

UK entrepreneurs have great ideas for digital health startups but the #NHS is standing in the way. My story bloomberg.com/news/articles/…

Aug 14, 2015

RT @Ostaley: UK entrepreneurs have great ideas for digital health startups but the #NHS is standing in the way. My story bloomberg.com/news/articles/…

Show 20 more tweets from Lisa Fleisher, Michael Bird and others...

Glaxo’s Best ‘Headache’ Remedy May Be Buying Stakes in Ventures

bloomberg.com — Two of GlaxoSmithKline's most promising businesses-its joint ventures in HIV drugs and consumer health-harbor both a threat and an opportunity, with a price tag in the billions. The minority owners of the units-Pfizer, Shionogi, and Novartis-can force Glaxo to buy them out by exercising so-called put options.
Aug 07, 2015

For $GSK, the best option for growth may be buying up all of the stakes in companies it already owns. My story: bloomberg.com/news/articles/…

Aug 07, 2015

RT @jwgale: @GSK's best ‘headache’ remedy may be buying stakes in ventures bloom.bg/1T9nonk via @business by @Ostaley

Aug 07, 2015

$GSK is facing a potential multi-billion dollar headache. Here's how to fix it (story by me): bloomberg.com/news/articles/…

Aug 07, 2015

$GSK's thriving ventures in @HIV and consumer health conceal a multi-billion dollar threat. Here's how to fix it: bloomberg.com/news/articles/…

Aug 07, 2015

RT @Ostaley: $GSK's thriving ventures in @HIV and consumer health conceal a multi-billion dollar threat. Here's how to fix it: bloomberg.com/news/articles/…

Merck’s Ebola Vaccine Found to Be Effective by Expert Panel

bloomberg.com — Merck & Co.'s vaccine for Ebola is "highly effective," according to an interim analysis from a panel of experts who recommended that a late-stage trial should continue. The vaccine was 100 percent effective when it was tested on more than 4,000 people who were in close contact with Ebola patients in the African nation of Guinea, the World Health Organization said, citing a study published today in the Lancet medical journal.
Jul 31, 2015

This is a huge deal for public health -- We have an #Ebola vaccine that was 100% effective in a big, big trial: bloom.bg/1hasa8l

Jul 31, 2015

RT @ArmstrongDrew: This is a huge deal for public health -- We have an #Ebola vaccine that was 100% effective in a big, big trial: bloom.bg/1hasa8l

Jul 31, 2015

RT @ArmstrongDrew: This is a huge deal for public health -- We have an #Ebola vaccine that was 100% effective in a big, big trial: bloom.bg/1hasa8l

Jul 31, 2015

Big news in the fight against #Ebola as @Merck vaccine is 100 pct effective in Guinea trials bloomberg.com/news/articles/…

Jul 31, 2015

Merck tested a vaccine on 4000 people who were in close contact with Ebola patients. It was 100 percent effective. bloom.bg/1hasa8l

Show 7 more tweets from Jesse Riseborough, John Tozzi and others...

AstraZeneca Earnings Beat Estimates as New Drugs Take Hold

bloomberg.com — AstraZeneca Plc, the U.K.'s second-largest drugmaker, reported core operating profit that beat analysts' estimates in the second quarter as sales of diabetes treatments and the blood thinner Brilinta helped offset declines in older medicines. Profit excluding some items was $1.81 billion, or $1.21 a share, compared with $2.03 billion, or $1.30 a share, a year earlier, the London-based company said in a statement.
Jul 30, 2015

$AZN manages to beat estimates, as new drugs show gains and old one do better than expected bloomberg.com/news/articles/…

Glaxo Aims for Next Wave of Cancer Drugs After Missing First

bloomberg.com — GlaxoSmithKline Plc shed more light on its pipeline of experimental medicines, giving a glimpse of drugs in earlier stages of development, although analysts remain skeptical about their promise. Glaxo has 40 drugs in the middle or final stages of clinical trials, Chief Executive Officer Andrew Witty said on Wednesday, and about half may be submitted to regulators or approved by 2020.

Glaxo Earnings Beat Estimates on AIDS Drugs, Cost Reductions

bloomberg.com — GlaxoSmithKline Plc, the U.K.'s biggest drugmaker, reported second-quarter earnings that declined less than analysts had estimated as AIDS medicines and efforts to reduce costs offset slumping revenue from Advair, its best-selling asthma drug. Profit excluding certain items was 1.3 billion pounds ($2.1 billion), or 17.3 pence a share, down from 1.4 billion pounds, or 19.1 pence a share, a year ago, the London-based company said today.

Sorin Slumps as Milan Court Casts Doubt on Cyberonics Deal

bloomberg.com — Sorin SpA had the biggest decline in almost seven years after the state's attorney in Milan filed a claim against the company that may delay its plans to combine with Cyberonics Inc. The state attorney views the planned transaction as intended to insulate Milan-based Sorin from potential liability related to environmental litigation against its previous parent, SNIA SpA, the combining companies said in a statement.

Finally! First malaria vaccine gets the nod after a 28-year journey

mgafrica.com — THE world's first vaccine for malaria has won the backing of European regulators, a critical step toward widespread immunisation against a disease that takes half a million lives every year in Africa. The Mosquirix vaccine from GlaxoSmithKline has been under development for 28 years.
Jul 25, 2015

Finally! First malaria vaccine gets the nod after a 28-year journey | Mail & Guardian Africa mgafrica.com/article/2015-0…

Jul 25, 2015

RT @cobbo3: Finally! First malaria vaccine gets the nod after a 28-year journey | Mail & Guardian Africa mgafrica.com/article/2015-0…

Aug 21, 2015

RT @cobbo3: Finally! First malaria vaccine gets the nod after a 28-year journey | Mail & Guardian Africa mgafrica.com/article/2015-0…

More Articles →
Feb 05, 2016

RT @YahooSports: Fallout of Louisville stripper scandal claims two innocent victims, @YahooForde writes. t.co/L6nYapZRFN t.co/OnexaPg4cT

Feb 04, 2016

The Secretive Hedge Fund That's Generating Huge Profits for Yale - Bloomberg Business bloomberg.com/news/articles/…

Feb 02, 2016

After Settlement, Florida State Shows Sympathy for Victim: Itself, via @nytimes nytimes.com/2016/01/30/spo…

Jan 29, 2016

RT @_StephenCastle: Rhodes won't fall in Oxford - university to keep benefactor's statue nyti.ms/1OTZyfR


Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.